Archives
-
Palonosetron and the Evidence Behind CINV Prevention
2026-10-10
Ruhlmann and Herrstedt’s review examines why palonosetron hydrochloride may differ from earlier 5-HT3 receptor antagonists, linking its long half-life, high receptor affinity, allosteric binding, and positive cooperativity to clinical evidence in chemotherapy-induced nausea and vomiting. The article’s main implication is that pharmacological distinctions are meaningful only when they translate into better control of acute or delayed emesis, improved nausea outcomes, or useful tolerability advantages.
-
PPZ1–TORC1 Ferroptosis in Candida albicans
2026-10-09
Miao and colleagues identify a PPZ1–TORC1 regulatory axis that links ferroptosis, autophagy, and antifungal resistance in Candida albicans. The study expands fungal ferroptosis research beyond iron overload by showing that a lipophilic oxidant can drive iron-dependent lipid peroxide accumulation and that PPZ1 loss increases ferroptotic sensitivity while weakening antifungal resistance.
-
Tariquidar and Viscosity-Linked P-gp Resistance
2026-10-08
Tariquidar (XR9576) is a research inhibitor used to investigate P-glycoprotein-mediated drug efflux and transporter-mediated drug disposition. A 2026 study links elevated extracellular fluid viscosity with P-gp upregulation and doxorubicin resistance through a mechanosensitive TRPV4–YAP pathway. The findings create a useful conceptual connection for drug resistance research, but they do not establish that tariquidar reverses viscosity-associated chemoresistance or has clinical benefit.
-
VX-661: Reading CFTR Rescue Evidence
2026-10-08
VX-661 is a F508del CFTR corrector whose effects depend on folding, trafficking, proteostasis, and channel function. This evidence-focused guide explains how calnexin biology and multi-layered readouts refine interpretation in cystic fibrosis research.
-
Clodronate Liposomes as a Causal Test in CRC Immunity
2026-10-07
Clodronate Liposomes provide a conceptual tool for testing how macrophage presence shapes colorectal cancer immunity. This evidence-focused guide connects liposome-encapsulated clodronate with the CCL7–TAM–CD8+ T-cell axis while clarifying what macrophage depletion can—and cannot—demonstrate.
-
Filipin III in Membrane Cholesterol Research
2026-10-07
Filipin III is a cholesterol-binding polyene macrolide antibiotic used conceptually to examine membrane-associated cholesterol. This overview places its reported imaging properties alongside a 2026 study linking SOAT1, cholesterol ester accumulation, lipophagy disruption and pulmonary fibrosis after PHMG exposure, while distinguishing established findings from possible research applications and highlighting important evidence limits.
-
A-769662: AMPK Evidence, Scope and Limits
2026-10-06
A source-grounded overview of A-769662 as an AMPK activator, emphasizing how its reported effects inform energy-stress and autophagy research, why AMPK activation does not always predict increased autophagy, and where evidence quality and model limitations constrain interpretation.
-
BV6: IAP Antagonist Evidence and Research Context
2026-10-06
BV6 is a Smac-mimetic IAP antagonist studied as a tool for probing apoptosis, cancer-cell sensitization and disease mechanisms. The supplied evidence includes supplier-reported cell and animal findings, but no supplied peer-reviewed study directly evaluates BV6. A 2025 ovarian-cancer muscle study provides useful pathway context while also showing why apoptotic markers alone do not establish causality.
-
Filipin III: Cholesterol Detection and Evidence
2026-10-05
Filipin III is a polyene macrolide antibiotic used as a cholesterol-binding probe for membrane studies. Its fluorescence and sterol-selective membrane effects support cholesterol detection in membranes, but the signal is a proxy rather than a direct measure of total cholesterol.
-
L-Ornithine in Liver–Brain Axis Research
2026-10-05
A source-grounded overview of L-Ornithine as a urea cycle intermediate in liver–brain axis research, examining the 2025 realgar-toxicity study, mechanistic evidence, conceptual applications, translational limits, and supplier-data boundaries.
-
Nelfinavir Mesylate: From Viral Protease to Proteostasis
2026-10-04
Nelfinavir Mesylate is an established HIV-1 protease inhibitor with a newer research connection to DDI2, NFE2L1, and ferroptosis biology. This evidence-focused analysis explains what the findings establish, where interpretation remains limited, and how the compound can frame questions across HIV infection research and cellular proteostasis.
-
JC-1 Mitochondrial Membrane Potential Assay
2026-10-03
The JC-1 Mitochondrial Membrane Potential Assay Kit provides a ratiometric proxy for mitochondrial membrane potential changes through red-to-green fluorescence. It can support apoptosis assay and mitochondrial function analysis, but it does not independently identify apoptosis or establish pathway causality.
-
Early Pheromones Rewire C. elegans Neurodegeneration
2026-10-01
Peng et al. show that pheromone exposure during the L1 stage can permanently remodel neuronal signaling and accelerate neurodegeneration in adult C. elegans. Their work identifies complementary ascr#3 and ascr#10 pathways linking ASK and ASI sensory neurons to AIA interneurons, insulin-like signaling, and neuronal autophagy.
-
DAPT (GSI-IX) in Corneal Cell Fate Assays
2026-10-01
DAPT (GSI-IX) offers a practical way to interrogate γ-secretase-dependent Notch and APP processing in controlled cell systems. This guide translates a corneal epithelial culture study into dose-finding, workflow, troubleshooting, and disease-model strategies without treating one concentration as universally optimal.
-
GLP-1 (9-36) amide: Assay Workflow Guide
2026-09-30
Learn how to use GLP-1 (9-36) amide as a controlled pharmacological perturbation in cAMP, receptor cross-talk, and metabolic assays. The workflow emphasizes fresh handling, orthogonal controls, and careful separation of product-specific observations from findings reported for related antagonists.